Cerus (CERS) FCF Margin (2010 - 2026)

Cerus (CERS) posted FCF Margin of 6.15% for Q2 2026, down 0.59% sequentially from 6.12% in Q1 2026, and down 58.0% YoY from 14.65% in Q2 2025.

Cerus (CERS) FCF Margin (2010 - 2026) Analysis & Trends

Cerus has reported FCF Margin for 17 years, with the latest figure at 6.15% in Q2 2026.

Quarterly FCF Margin fell 58.0% year-over-year to 6.15% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.73% (down 234.0% YoY) and the FY2025 annual result came in at 0.47%, down 376.0% from the prior year.
FCF Margin eased to 6.15% in Q2 2026 per CERS's latest filing, from 6.12% in the prior quarter.
Over five years, FCF Margin peaked at 7.28% in Q3 2024 and troughed at 57.6% in Q1 2022.
A 5-year average of 9.84% and a median of 4.91% in 2022 frame the typical range for FCF Margin.
The sharpest annual moves came in 2023 and 2024: FCF Margin slumped 2635 bps in 2023, then surged 4028 bps in 2024.
Over 5 years, FCF Margin stood at 4.25% in 2022, then tumbled by 362 bps to 19.66% in 2023, then surged by 128 bps to 5.5% in 2024, then gained by 4 bps to 5.73% in 2025, then plunged by 207 bps to 6.15% in 2026.
According to Business Quant data, FCF Margin over the past three periods registered 6.15%, 6.12%, and 5.73% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	15.81%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	16.07%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	21.26%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	23.50%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	33.60%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	14.10%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	1.28%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	5.32%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	18.73%
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn	-6.15%

Download Data